Supplemental financial information

3 Months Ended

Mar. 31, 2020

3. Supplemental financial information

Cash, cash equivalents and restricted cash

Cash and cash equivalents consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows (amounts in thousands).


	As of		As of
	March 31,		December 31,
	2020		2019
Cash and cash equivalents	$	121,020	$	98,849
Short-term and long-term restricted cash		345		345
Total cash, cash equivalents, and restricted cash shown in the statements of cash flows	$	121,365	$	99,194

Prepaid expenses and other current assets

Prepaid expenses and other current assets consist of the following (in thousands):


	As of		As of
	March 31,		December 31,
	2020		2019
Prepaid clinical	$	2,547	$	3,719
Prepaid insurance		544		994
Prepaid manufacturing costs		717		558
Other prepaid expenses and current assets		306		366
Total prepaid expenses and other current assets	$	4,114	$	5,637

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):


	As of		As of
	March 31,		December 31,
	2020		2019
Employee-related expenses	$	562	$	1,925
Development costs and sponsored research		673		652
Clinical trials		1,135		410
Other		426		354
Total accrued expenses and other current liabilities	$	2,796	$	3,341